Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 11INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Neoplasms 10Breast Neoplasms 9Prostatic Neoplasms 7Multiple Myeloma 6Colorectal Neoplasms 5Ovarian Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Neoplasms, Plasma Cell 3Lung Neoplasms 3Hematologic Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Neoplasms by Site 2Mycoses 2Medication Adherence 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia 2Carcinoma, Transitional Cell 2COVID-19 2Adenocarcinoma 2Uveal Melanoma 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × Standard of Care × Clear all
NCT03602859 2025-12-31

FIRST

Tesaro, Inc.

Phase 3 Active not recruiting
1,400 enrolled 18 charts
Gynecologic

Ovarian Neoplasms

NCT02107937 2022-05-04

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma

Sotio Biotech Inc.

Phase 2 Completed
136 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02107950 2018-08-15

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

Sotio Biotech Inc.

Phase 2 Completed
71 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02107378 2016-11-30

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

Sotio Biotech Inc.

Phase 2 Terminated
22 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡